← Back to Search

Procedure

PA-LAA shunt for Left Atrial Appendage Thrombus Prevention (PA-LAA Trial)

N/A
Waitlist Available
Led By Benjamin Hibbert, MD PhD
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

PA-LAA Trial Summary

This trial will test a new, minimally invasive procedure to treat atrial fibrillation and reduce the risk of stroke.

Eligible Conditions
  • Left Atrial Appendage Thrombus Prevention

PA-LAA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Composite of device safety and performance
Secondary outcome measures
Device related performance - maintaining patency
Need for intervention to close the shunt
Systemic embolization
+1 more

PA-LAA Trial Design

1Treatment groups
Experimental Treatment
Group I: Procedure armExperimental Treatment1 Intervention
At the time of surgery a covered stent will be inserted through the atriotomy into the left pulmonary artery and balloon dilated to stabilize the device. The target shunt diameter will be 3.5-4 mm to minimize LAA stasis.

Find a Location

Who is running the clinical trial?

Ottawa Heart Institute Research CorporationLead Sponsor
188 Previous Clinical Trials
92,436 Total Patients Enrolled
Benjamin Hibbert, MD PhDPrincipal InvestigatorOttawa Heart Institute Research Corporation
2 Previous Clinical Trials
236 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025